Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Biocryst Pharmaceuticals Q3 2026 Results: Net Income $37.9M, Up 193.9% YoY

BioCryst Pharmaceuticals reported 257,299,269 shares of common stock outstanding as of October 30, 2026. The filing highlights the commercialization of ORLADEYO, the strategic merger with Astria, and a shift toward prioritizing external innovation and clinical development of product candidates like navenibart.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue180.3159.4
Profit before tax38.612.1
Net income37.912.9
EPS (diluted, $ a share)$0.14$0.06

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Net income, year on year+193.9%
Revenue, year on year+13.1%
Operating margin29.6%
Source

10-Q filed with the SEC, NASDAQ: BCRX. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Biocryst Pharmaceuticals Inc: key numbers

Share price
$7.50Close, Nov 17
Market cap
$1.93B
Shares outstanding
257.3MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Biocryst Pharmaceuticals Inc

All →
7:03 AM ET 8-K
Financial Results

Biocryst Pharmaceuticals Financial Results

BioCryst reported Q3 2026 total net revenue of $180.3 million, driven by $174.8 million in ORLADEYO sales, and achieved an operating profit of $53.3 million. The company increased its full-year total revenue guidance to $715-$730 million and highlighted the recent FDA approval of ORLADEYO oral pellets for patients aged 12 and older.

Term
3 years

“In the third quarter, we delivered continued growth of ORLADEYO and strong profitability while broadening the foundation for our long-term success.”

Charlie Gayer, President and Chief Executive Officer

“This progress across our business increases our confidence in our ability to drive sustainable growth and lasting value for patients and shareholders.”

Charlie Gayer, President and Chief Executive Officer

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.